Dechra Pharmaceuticals PLC Directorate Change (8938S)
November 19 2021 - 1:00AM
UK Regulatory
TIDMDPH
RNS Number : 8938S
Dechra Pharmaceuticals PLC
19 November 2021
19 November 2021
Dechra(R) Pharmaceuticals PLC
("Dechra" or "the Company")
Directorate Changes
Dechra is pleased to announce that following a comprehensive
search process Alison Platt will be appointed as Chair with effect
from 1 January 2022 . Tony Rice will step down from the Board on 31
December 2021.
Alison joined the Dechra Board as a Non-Executive Director in
March 2020, she has extensive board experience gained in
non-executive roles at, Bupa Arabia, Cable & Wireless, Skills
for Health and the Foreign and Commonwealth Office. Alison is
currently a Non-Executive Director at Tesco PLC, Spectrum Life and
Chair of Legal & General Financial Advice.
In September 2021, the Company announced that Tony Rice, who has
been Chairman for five years, wished to retire from the Board to
devote more time to family and other business and charitable
activities.
Dechra also announces today that Denise Goode, Non-Executive
Director, has informed the Board that due to other commitments she
has decided to tender her resignation and step down from the Board
and leaves the Company on 30 November 2021.
Julian Heslop will re-assume the role of Audit Committee
Chairman until a successor is appointed.
Ian Page, Chief Executive Officer, Dechra said:
"I am delighted that Alison has accepted the Chair following
Tony's retirement at the end of the year. I look forward to working
with Alison in her new role. Since joining us as a Non-Executive
Director in 2020 Alison has gained a good understanding of Dechra
and our culture. Her extensive leadership experience and skills
will further enhance the team's capabilities. I would also like to
acknowledge Tony's contribution to the development of the Group. We
wish him all the best."
"I would like to thank Denise for her positive and professional
contribution to the Group. I wish her all the very best for the
future."
Alison Platt added:
"I am delighted to have been offered the position as Dechra's
Chair and very much look forward to continuing to work with
everyone at Dechra and continuing to build on the successful growth
of the Company."
Commenting on the above changes Tony Rice, Dechra's Chairman
added:
" It has been my privilege and pleasure to work with Ian, his
management team and the Board and be part of its evolution,
witnessing its growth, and the delivery of great products and
services to our customers whilst returning strong returns to our
shareholders."
"I would like to also congratulate Alison on her forthcoming
appointment and to wish Denise every success in her future
too."
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com Office: +44 (0) 121 309 0099
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture marketing and sales of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
Market Abuse Regulation (MAR)
The information contained within this announcement may contain
inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014. Upon the publication of this announcement via
the Regulatory Information Service, this inside information is now
considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGPGBGGUPGGRR
(END) Dow Jones Newswires
November 19, 2021 02:00 ET (07:00 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024